Skip to main content

Cardiff Oncology, Inc.

corporate_fare Company Profile

Cardiff Oncology, Inc.

CRDF·NASDAQ·Life Sciences·CIK 0001213037

We are a clinical-stage biotechnology company focused on developing new therapies for various cancers by inhibiting PLK1, a known target in oncology. Our strategy involves combining onvansertib, our oral and highly selective PLK1 inhibitor, with standard-of-care treatments to target tumor vulnerabilities. Our clinical program primarily focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC). We also have investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Our clinical development uses tumor genomics and biomarker assays to select patients and assess their treatment response. Our lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that specifically inhibits PLK1 and has a 24-hour half-life. Onvansertib is highly potent and selective against the PLK1 enzyme (IC 50 = 2nM), unlike previous PLK1 inhibitors that targeted multiple PLK targets. It showed low or no activity on 63 other kinases (IC 50 >500 nM), including PLK2 and PLK3 (IC 50 >10,000 nM). Onvansertib is orally bioavailable, offering flexible dosing. Its relatively short 24-hour half-life also allows for flexible dosing and scheduling, which has shown a favorable safety profile in multiple clinical trials. In laboratory studies, onvansertib demonstrated synergistic effects when combined with various cytotoxic agents, including microtubule-targeting agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, PARP inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.

Cardiff Oncology, Inc. (NASDAQ:CRDF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for CRDF at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Licensor Terminates Key Onvansertib Agreement; Cardiff Oncology Vows to Fight
  • Cardiff Oncology Sues Partner Over Lead Drug Patent Dispute, Escalating License Battle
  • Cardiff Oncology Sues NMS Over Critical Onvansertib License Dispute
  • FDA Agrees to Phase 3 Design for Onvansertib, Boosting Cardiff Oncology's Key Drug Path
  • Cardiff Oncology Reports Short Cash Runway, Advances Lead Drug to Phase 3 with FDA Alignment

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$593K
Net Income
-$45.85M
Diluted EPS
-$0.69
Op. Cash Flow
-$37.92M
Free Cash Flow
-$37.97M
Operating Income
-$48.96M
Cash & Equivalents
$17.47M
Debt / Equity
0.00×
Net Margin
-77.32×
Shares Outstanding
68.31M sh
Source: 10-K · filed 2026-02-24 · accession 0001193125-26-067464
$0.8358 -1.99% today
52-week range · as of 2026-11-12 $0.7202 – $3.31
Market cap
$66.34M
Volume
521K (0.4× avg)
3-mo avg 1.3M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRDF - Filings & News (Page 2)

CRDF
May 29, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.87
Real-time Price: $0.8358 info
Change: -$1.03 (-55%) info
Market Cap: $66.344M info
CRDF
May 19, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.78
Real-time Price: $0.8358 info
Change: -$0.9442 (-53%) info
Market Cap: $66.344M info
CRDF
May 19, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $0.8358 info
Change: -$0.9442 (-53%) info
Market Cap: $66.344M info
CRDF
May 15, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $0.8358 info
Change: -$0.9037 (-52%) info
Market Cap: $66.344M info
CRDF
May 14, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.73
Real-time Price: $0.8358 info
Change: -$0.8942 (-52%) info
Market Cap: $66.344M info
CRDF
May 14, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.69
Real-time Price: $0.8358 info
Change: -$0.8542 (-51%) info
Market Cap: $66.344M info
CRDF
Apr 23, 2026, 4:45 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $0.8358 info
Change: -$0.8542 (-51%) info
Market Cap: $66.344M info
CRDF
Apr 23, 2026, 4:44 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.69
Real-time Price: $0.8358 info
Change: -$0.8542 (-51%) info
Market Cap: $66.344M info
CRDF
Apr 09, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $0.8358 info
Change: -$0.7942 (-49%) info
Market Cap: $66.344M info
CRDF
Apr 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.66
Real-time Price: $0.8358 info
Change: -$0.8212 (-50%) info
Market Cap: $66.344M info
CRDF
Apr 02, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $0.8358 info
Change: -$0.7442 (-47%) info
Market Cap: $66.344M info
CRDF
Feb 25, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.77
Real-time Price: $0.8358 info
Change: -$0.9342 (-53%) info
Market Cap: $66.344M info
CRDF
Feb 24, 2026, 5:09 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.77
Real-time Price: $0.8358 info
Change: -$0.9361 (-53%) info
Market Cap: $66.344M info
CRDF
Feb 24, 2026, 5:07 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.77
Real-time Price: $0.8358 info
Change: -$0.9361 (-53%) info
Market Cap: $66.344M info
CRDF
Jan 27, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.04
Real-time Price: $0.8358 info
Change: -$1.20 (-59%) info
Market Cap: $66.344M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets